BlackRock Group’s Heron Therapeutics HRTX Stock Holding History

BlackRock Group’s Portfolio HRTX Stock Details HRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	$164K	Buy	12,582 +1,237	+11%	+$19.4K	﹤0.01%	2716
2016 Q3	$196K	Buy	11,345 +529	+5%	+$9.81K	﹤0.01%	2634
2016 Q2	$195K	Buy	10,816 +897	+9%	+$17.5K	﹤0.01%	2591
2016 Q1	$188K	Buy	9,919 +6,301	+174%	+$124K	﹤0.01%	2594
2015 Q4	$97K	Sell	3,618 -11,382	-76%	-$304K	﹤0.01%	2689
2015 Q3	$366K	Buy	+15,000	New	+$500K	﹤0.01%	2322

Other funds holding HRTX

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

JHIU

Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return

Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return

KCM

Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

HCMT

Highland Capital Management (Texas) Dallas, Texas $39M AUM

BlackRock Group's HRTX Position: Q4 2016 in Review

BlackRock Group increased its Heron Therapeutics (HRTX) stake by 11% in Q4 2016, buying an estimated $19.4K and bringing the position to 12,582 shares worth $164K. The position accounts for ﹤0.01% of the portfolio, ranked #2716.

BlackRock Group first reported a position in HRTX in Q3 2015 and has held it in 6 quarters since. The position peaked at $366K in Q3 2015. 99 funds tracked by Wall St. Rank hold HRTX as of Q4 2016.

BlackRock Group held 12,582 shares of Heron Therapeutics worth $164K as of Q4 2016.
BlackRock Group bought 1,237 Heron Therapeutics shares in Q4 2016, an estimated $19.4K.
Heron Therapeutics made up ﹤0.01% of BlackRock Group's portfolio in Q4 2016, its #2716 holding.
BlackRock Group first reported a position in Heron Therapeutics in Q3 2015 and has held it in 6 quarters since.
BlackRock Group's Heron Therapeutics position peaked at $366K in Q3 2015.
99 funds tracked by Wall St. Rank held Heron Therapeutics as of Q4 2016.

Based on BlackRock Group's 13F filing for Q4 2016, filed 10 Feb 2017.